Phase Ib/IIa study of AV4025, an HCV NS5A Inhibitor in HCV-infected patients
Latest Information Update: 11 Apr 2016
At a glance
- Drugs AV 4025 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 11 Apr 2016 New trial record